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ABSTRACT 
 
Human immunodeficiency virus (HIV) and human papillomavirus (HPV) are both sexually 
transmitted pathogens. As the most prevalent sexually transmitted infection in the world, HPV 
affects both men and women across many demographic categories. Although HPV often clears 
without treatment, persistent infection can cause dysplasia which can progress to cancer. HPV 
vaccines, licensed in the US since 2006, hold promise for reducing not only infection rates but 
also incidence of HPV-associated cancers. Albeit less prevalent than HPV, HIV still represents a 
considerable health burden worldwide even in an era of effective combination anti-retroviral 
therapy (cART). In the US, the majority of new HIV cases arise among gay and bisexual men. 
Despite billions of dollars and years devoted to research, an effective HIV vaccine remains 
elusive. 
Since HIV-positive individuals are more susceptible to other infections even while on anti-
retroviral therapy, they are also prone to HPV infection and associated anal dysplasia. 
Additionally, a growing body of evidence suggests that HPV also impacts the acquisition of HIV. 
The axes of interactions between these two viral infections are not yet fully understood. 
The overall objective of this study was to further elucidate the relationship between HIV and 
HPV infection in anal dysplasia/cancer by assessing HPV infection in the context of HIV and 
vice versa. The central hypotheses were that HIV-positive individuals present more frequently 
with HPV infection and associated anal dysplasia and that HIV seroconversion may occur 
subsequent to HPV infection. 
First, the study demonstrated that HPV at non-anal sites may be associated with anal 
dysplasia/cancer among HIV-positive males. The presence of HPV and the number of HPV 
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genotypes at anatomical sites other than the anus trended toward higher odds of ASIL. 
Presence of HPV and the number of HPV genotypes at the penile shaft conferred the highest, 
statistically significant odds of ASIL – greater odds than conferred by presence of HPV and the 
number of HPV genotypes at the anus itself. 
Second, the study showed the potential of HPV quantitation for enhanced screening and 
diagnosis of anal dysplasia/cancer in the context of HIV infection. All participants with HGAIN 
had HPV-16 E6 DNA levels above 10 copies per cell. Participants with LGAIN or Negative 
biopsy results and low HPV-16 E6 copy could potentially have avoided invasive HRA if HPV 
quantitation were used as a supplemental diagnostic marker for anal dysplasia. 
Third, the study explored the effect of prior HPV infection on acquisition of HIV. Among MSM 
and TG women in the Thai Test & Treat cohort, HPV acquisition appeared to increase the risk of 
subsequent HIV seroconversion. Despite remaining ambiguity over HPV’s role in HIV 
acquisition, some researchers are advocating for study of HPV vaccination as a means for 
reducing HIV incidence. 
This study has contributed to the body of knowledge in the field by identifying new diagnostic 
indicators of HPV-associated anal dysplasia and by providing additional evidence for HPV’s 
influence on HIV acquisition. Further investigation will permit validation of these novel diagnostic 
markers and innovative strategy for reducing the global incidence of HIV. 
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INTRODUCTION 
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PROJECT SUMMARY 
 
Human immunodeficiency virus (HIV) and human papillomavirus (HPV) are both sexually 
transmitted pathogens. As the most prevalent sexually transmitted infection in the world, HPV 
affects both men and women across many demographic categories. Although HPV often clears 
without treatment, persistent infection can cause dysplasia which can progress to cancer. HPV 
vaccines, licensed in the US since 2006, hold promise for reducing not only infection rates but 
also incidence of HPV-associated cancers. Albeit less prevalent than HPV, HIV still represents a 
considerable health burden worldwide even in an era of effective combination anti-retroviral 
therapy (cART). In the US, the majority of new HIV cases arise among gay and bisexual men. 
Despite billions of dollars and years devoted to research, an effective HIV vaccine remains 
elusive. 
Since HIV-positive individuals are more susceptible to other infections even while on anti-
retroviral therapy, they are also prone to HPV infection and associated anal dysplasia. 
Additionally, a growing body of evidence suggests that HPV also impacts the acquisition of HIV. 
The axes of interactions between these two viral infections are not yet fully understood. 
The overall objective of this study was to further elucidate the relationship between HIV and 
HPV infection in anal dysplasia/cancer by assessing HPV infection in the context of HIV and 
vice versa. The central hypotheses were that HIV-positive individuals present more frequently 
with HPV infection and associated anal dysplasia and that HIV seroconversion may occur 
subsequent to HPV infection. 
To better understand the interaction between these two viruses, specimens from multiple 
anatomical sites of HIV patients were tested for HPV and association with anal dysplasia. 
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Furthermore, HPV-16 E6 DNA in anal cytology specimens of HIV patients was quantitated to 
analyze correspondence to anal cytology or anal biopsy grade. Finally, HPV infection was 
assessed as a precursor to HIV seroconversion. Results from this study may provide additional 
insight for diagnosis of HPV-associated anal dysplasia among HIV-positive patients, and 
clarification of HPV’s role in HIV acquisition may suggest another avenue for reducing HIV 
transmission in high-risk populations. 
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HUMAN IMMUNODEFICIENCY VIRUS (HIV) 
 
Human immunodeficiency virus (HIV) is a member of the Retroviridae virus family. Its structure 
includes a spherical envelope and conical nucelocapsid that is faintly discernible in Figure 1 [1]. 
As a retrovirus, its genome consists of two positive-sense single-stranded ribonucleic acid 
(RNA) sequences that must be reverse transcribed into deoxyribonucleic acid (DNA) before viral 
replication can occur. HIV’s hallmark is its ability to infect immune cells by binding to CD4 
receptors on T cells and macrophage-lineage cells. By infecting the host’s immune cells, it not 
only causes disease – acquired immunodeficiency syndrome (AIDS) – but also inhibits the 
immune system’s ability to respond to the infection. Primary modes of transmission are through 
blood or sexual contact although vertical transmission from mother to child is also possible 
during childbirth and breastfeeding [2]. 
  
 
 
Figure 1. Micrograph of HIV showing spherical envelope and conical nucleocapsid [1] 
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In 2014, there were an estimated 36.9 million people living with HIV worldwide, 2.0 million new 
HIV infections, and 1.2 million deaths attibuted to AIDS as shown in Figure 2  [3]. The 
overwhelming burden of HIV/AIDS lies in sub-Saharan Africa followed by Asia and the Pacific 
region. 
 
 
 
Figure 2. Estimated global burden of HIV in 2014 [3] 
 
In the same year, there were 44,609 new HIV infections reported among adults and adolescents 
in the United States (US) for a total incidence rate of 16.6 new HIV infections per 100,000 
people as shown in Figure 3 [4]. Higher incidence rates (new HIV infections per 100,000 people) 
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were common among southern US states – Louisiana (36.6), Florida (31.3), Georgia (27.0), 
Texas (22.1), Mississippi (21.0), and South Carolina (20.7) – and in some densely populated 
states – Maryland (27.7), New York (22.8), and New Jersey) (20.4) – and cities like Washington, 
DC (66.9). Relatively high incidence rates also occurred in the territories of the US Virgin 
Islands (27.4) and Puerto Rico (22.7). In Hawaii, HIV incidence actually fell below the national 
average at 9.2 new HIV infections per 100,000 people. 
 
 
 
Figure 3. US HIV Incidence in 2014 [4] 
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As previously mentioned, HIV primarily infects CD4 T cells that are responsible for mounting an 
adaptive immune response to the pathogen. Illustrated in Figure 4 [5], the acute phase of HIV 
infection is marked by a steep increase in viral load with a corresponding precipitous drop in 
CD4 T cell counts. The infection can then enter a lengthy chronic phase of clinical latency when 
the viral load reaches a setpoint and CD4 counts stabilize. However, when HIV viral loads 
resurge and cause CD4 counts to plummet below 200 cells/mm3, then the infection has reached 
the stage of full-blown AIDS. It is at this point that opportunisitic infections and other 
complications more commonly lead to death attributable to HIV infection and AIDS. 
 
 
Figure 4. HIV Time Course without Treatment [5] 
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With the advent of combination anti-retroviral therapy (cART), viral replication can be 
suppressed, CD4 T cell counts may rebound, and HIV-positive individuals can live to near 
normal life expectancies. However, the immune system never quite returns to the same level  of 
function as before HIV infection. Even while on effective cART, HIV patients are susceptible to 
secondary infections and complications, including human papillomavirus (HPV) infection and 
associated dysplasia/cancer [6, 7]. 
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HUMAN PAPILLOMAVIRUS (HPV) 
 
Human papillomavirus (HPV) is a member of the Papillomaviridae virus family. Its structure 
includes an icosahedral nucelocapsid but no envelope as illustrated in Figure 5 [8]. Its genome 
consists of an approximately 8,000 base-pair sequence of double-stranded deoxyribonucleic 
acid (dsDNA). The virus is purported to bind to heparan sulfate proteoglycans (HSPGs) to infect 
basal epithelial cells. Primary modes of transmission are through sex or direct skin contact 
although vertical transmission from mother to child can result in respiratory papillomatosis [9]. 
 
 
 
Figure 5. Micrograph of HPV showing icosahedral nucelocapsid [8] 
 
HPV is the most prevalent sexually transmitted infection in the world. The most recent update 
from the National Health and Nutrition Examination Survey (NHANES) found that more than 
40% of US adults aged 18 to 59 years are infected with genital HPV [10]. Chesson et al. 
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estimated that greater than 80% of men and women in the US would acquire HPV by the age of 
45 in the absence of HPV vaccination [11].  
HPV infection causes a variety of cancers -- an estimated 30,700 cases per year among men 
and women in the US, including 4,600 anal cancers [12]. Among HIV-positive individuals, 
incidence of anal HPV and anal cancer is particularly high, even while on effective cART [6, 7]. 
As depicted in Figure 6, even moderate reduction in CD4 count places HIV-positive men who 
have sex with men (MSM) at higher risk of anal HPV infection and abnormal anal cytology than 
HIV-negative MSM [13]. With increasing incidence of anal cancer among HIV patients, annual 
anal cytology screening is recommended for this high-risk population [14]. 
 
 
Figure 6. Percentage of HIV-positive and HIV-negative MSM 
with Anal HPV Infection and Abnormal Anal Cytology [13] 
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Although more than 200 genotypes of HPV have been discovered [15], only around 40 types 
are known to infect the anogenital region. Low-risk HPV genotypes 6 and 11 are associated with 
approximately 90% of anogenital warts. High-risk HPV genotypes 16 and 18 are responsible for 
about 70% of cervical cancers in the US. Several other HPV genotypes are also considered 
high-risk for anogenital cancers though generally detected at lower frequencies. The most 
important risk factor for the development of HPV-associated cancer is persistent infection with 
one or more oncogenic HPV genotypes. 
The progression from HPV infection to dysplasia and cancer can take years or even decades. 
Molecular mechanisms leading to development of dysplasia and cancer involve integration of 
HPV’s viral DNA with the host cell’s own genome. Integration of viral E6 and E7 oncogenes may 
be accompanied by loss of the viral E2 gene, which typically represses expression of E6 and E7. 
When E6 oncoprotein binds to p53, it marks the cell cycle checkpoint inhibitor for ubiquitin-
mediated degradation, allowing unfettered cellular proliferation. Meanwhile, when E7 
oncoprotein binds the retinoblastoma protein pRb, it releases transcription factor E2F to initiate 
cell cycle activation and cellular proliferation. These molecular pathways are depicted in Figure 
8 [16]. With the loss of E2 repression, increased expression of HPV E6 and E7 oncogenes 
induces the dysregulated cellular proliferation characteristic of cancer. 
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Figure 7. Increased expression of HPV E6 and E7 oncogenes induces 
dysregulated cellular proliferation characteristic of cancer [15] 
 
 
Fortunately, effective vaccines targeting the most clinically relevant HPV types became 
available roughly one decade ago. Cervarix, developed by GlaxoSmithKline, targets high-risk 
genotypes 16 and 18 to prevent about 70% of HPV-associated cancers. Gardasil, marketed by 
Merck, targets high-risk genotypes 16 and 18 as well as low-risk genotypes 6 and 11 to prevent 
approximately 70% of HPV-associated cancers and 90% of anogenital warts. Gardasil 9 is 
Merck’s newest entry in the HPV vaccine market. It targets five additional oncogenic HPV types 
to prevent approximately 90% of HPV-associated cancers and 90% of anogenital warts. HPV 
genotypes associated with cervical cancer and available vaccines are shown in Figure 8 [17]. 
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Figure 8. Frequency of HPV genotypes associated with cervical cancer, 
including highest risk types targeted by available vaccines [16] 
 
Surveillance data from the past decade indicate that HPV infection has decreased in proportion 
with the population vaccinated against HPV. Statistics from Australia also suggest successful 
reduction in incidence of anogenital warts as a consequence of HPV vaccination [18]. Due the 
slow progression from HPV infection to associated dysplasia and cancer, data is not yet 
available to determine the effect of HPV vaccination on cancer incidence. 
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SPECIFIC AIMS 
 
HPV is the most prevalent sexually transmitted infection in the world. The most recent update 
from the National Health and Nutrition Examination Survey (NHANES) found that more than 
40% of US adults aged 18 to 59 years are infected with genital HPV [19]. HPV infection causes 
a variety of cancers -- an estimated 30,700 cases per year among men and women in the US, 
including 4,600 anal cancers [12]. Among HIV-positive individuals, incidence of anal HPV and 
anal cancer is particularly high, even while on effective cART [6, 7]. With increasing incidence of 
anal cancer among HIV patients, annual anal cytology screening is recommended for this high-
risk population [14]. 
While many studies have examined HPV as a consequence of HIV infection, relatively few have 
scrutinized HPV as a precursor to HIV infection; however, a growing body of literature suggests 
that HPV does impact the acquisition of HIV [20-24]. With these bi-directional influences in mind, 
the overall objective of this study was to further elucidate the relationship between HIV and HPV 
infection in HPV-associated anal dysplasia in the context of HIV and evaluate the effect of HPV 
infection on subsequent HIV seroconversion. The central hypotheses stated not only that HIV-
positive individuals present more frequently with HPV infection and associated anal dysplasia 
but also that HIV seroconversion may occur subsequent to HPV infection. 
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To test the central hypotheses, the following specific aims were pursued: 
 
1. Determine the association between detectable HPV at various anatomical sites and 
atypical anal cytology among HIV-positive individuals in Hawaii. 
The hypothesis was that anal squamous intraepithelial lesions (ASIL) are associated with 
detectable high-risk HPV genotypes in anal specimens as well as HPV detectable across 
multiple anogenital sites. 
2. Differentiate high-grade anal intraepithelial neoplasia (HGAIN) from low-grade anal 
intraepithelial neoplasia (LGAIN) or negative anal biopsies using HPV type-specific 
DNA quantitation. 
The hypothesis was that HGAIN is associated with higher copy numbers of HPV-16 E6 DNA 
than LGAIN or negative anal biopsies. 
3. Determine whether an association exists between HIV seroconversion and acquisition 
or clearance of anal HPV genotypes in a Thai cohort. 
The hypothesis was that HPV clearance is associated with HIV seroconversion in a high-risk 
population. 
 
The results from this study demonstrated innovation and positive translational impact by 
identifying new diagnostic indicators of HPV-associated anal dysplasia and by suggesting a new 
approach for reducing HIV transmission.   
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 SPECIFIC AIM 1 
 
Determine the association between detectable HPV at various anatomical sites 
and atypical anal cytology among HIV-positive individuals in Hawaii. 
 
Hypothesis: Anal squamous intraepithelial lesions (ASIL) are associated with detectable high-
risk HPV genotypes in anal specimens as well as HPV detectable across multiple anogenital 
sites. 
 
Rationale: HIV-positive individuals are at higher risk for anal HPV infection and associated anal 
dysplasia/cancer. As the most common sexually transmitted infection in the world, HPV may be 
present at multiple anatomical sites, influencing the development of HPV-associated anal 
dysplasia/cancer. 
 
  
 
 
 
 
 
CHAPTER 2 
 
HUMAN PAPILLOMAVIRUS AT MULTIPLE SITES ASSOCIATED 
WITH ANAL SQUAMOUS INTRAEPITHELIAL LESIONS 
IN HIV-SEROPOSITIVE INDIVIDUALS 
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ABSTRACT 
 
Objective. HIV-seropositive patients have higher risk of HPV infection even on anti-retroviral 
therapy. Infection with high-risk HPV genotypes can cause dysplasia leading to cancer. This 
study assessed HPV at different anatomical sites in HIV-seropositive individuals and factors 
associated with anal squamous intraepithelial lesions (ASIL). 
Methods. Specimens were obtained from multiple anatomical sites for each participant in 
conjunction with routine screening for anal dysplasia. Female specimens included cervical and 
anal cytologies and oral wash. Male specimens included anal cytologies, oral wash, and 
exfoliated cells from penile head, penile shaft, scrotum, and from uncircumcised subjects, inner 
foreskin. Demographic and clinical characteristics were recorded. Following DNA extraction, 
HIV DNA copy was assessed by qPCR; HPV was genotyped. Statistical analyses included 
calculation of odds ratios (OR) and 95% confidence intervals (CI), t-tests or Mann-Whitney tests. 
Results. Males were more likely to have ASIL: 29/50 (58%) compared to 1/11 females (9%) 
(OR=13.81, 95% CI: 1.64-116.32). HPV 6 or 11 in anal specimens was significantly associated 
with ASIL (OR= 6.29, 95% CI: 1.49-26.44). Number of HPV genotypes in anal specimens was 
also significant: ASIL+ (3.4±3.1) versus ASIL- (1.6±3.1) (p=0.009). Among 44 males, HPV was 
detected from at least one anatomical site for 33 participants (75%): 27 anus (61%), 19 oral 
wash (44%), 17 penile shaft (39%), 11 scrotum (26%), 10 penile head (23%), 0 foreskin. 
Detection of HPV in penile shaft specimens was significantly associated with ASIL (OR=6.79, 
95% CI: 1.57-29.36) as was number of HPV genotypes in penile shaft specimens: ASIL+ (2.4 ± 
4.0) versus ASIL- (0.6 ± 1.7) (p=0.025). 
Only 1/11 females had ASIL; only 1/11 females had cervical dysplasia: OR was not estimable 
due to small numbers.  
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Conclusions. Males were more prone to ASIL than females. HPV at anal as well as non-anal 
sites may be indicative of ASIL. 
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INTRODUCTION 
 
Individuals infected with human immunodeficiency virus type 1 (HIV) are at increased risk for 
human papillomavirus (HPV) infection and for anal dysplasia/cancer [1-4]. Presence of multiple 
HPV genotypes as well as presence of HPV at other anatomical sites potentially increase the 
risk for anal dysplasia/cancer [1, 2, 5, 6]. While high-risk HPV genotypes are found in more than 
90% of anal cancers among HIV-infected patients, there may be additional factors that lead to 
anal dysplasia/cancer [6, 7]. Co-infection with HIV and HPV in the anal canal and presence of 
HPV at other anatomical sites may support ongoing exposure to HPV and/or HIV-related 
immune suppression, leading to increased risk for dysplasia/cancer. Recent data suggest that 
the continued persistence of HIV DNA in circulating monocytes in patients treated with 
combination anti-retroviral therapy (cART) leads to progression of HIV disease itself and other 
HIV-associated complications, which may include HPV infection and associated anal neoplasia 
[8-11]. The objective of this study was to evaluate specimens from various anatomical sites of 
the same HIV-positive individual for HPV genotypes in relation to anal squamous intraepithelial 
lesions (ASIL). We hypothesized that ASIL would be associated with presence of HPV at 
multiple anatomical sites. 
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MATERIALS AND METHODS 
 
During a 12-month period, men and women, 18-65 years of age, were either self-referred or 
referred by community physicians for anal dysplasia/cancer screening in collaboration with the 
Hawaii Center for AIDS, University of Hawaii (UH), and UH Cancer Center. Subjects were 
included if HIV-positive regardless of previous history of HPV infection, anal dysplasia/cancer, 
or related treatment. Participants provided written consent in accordance with UH Institutional 
Review Board policy. Two anal cytology specimens were collected with a Dacron swab [12] and 
stored in ThinPrep collection medium (Hologic, Inc., Bedford, MA). One anal specimen was 
processed by a CLIA-certified clinical laboratory with cytopathology reviewed and reported by 
the same experienced cytopathologist (JK) according to the Bethesda system: anal cytology 
was evaluated, using criteria and terminology adapted from standardized cervical cytology 
screening [6, 13-19]. The other anal specimen was assayed for HPV and HIV DNA. Anal 
cytology specimens were assessed for adequacy and categorized as 1) Negative (ASIL-) if no 
cellular changes could be detected or if cellular changes were caused by inflammation or 
reparative process or 2) Positive for anal squamous intraepithelial lesions (ASIL+) if abnormal 
cytological changes were found, including high-grade squamous intraepithelial lesions (HSIL), 
low-grade squamous intraepithelial lesions (LSIL), atypical squamous cells of undetermined 
significance (ASC-US), and atypical squamous cells which cannot exclude HSIL (ASC-H). Oral 
wash specimens were collected according to methods previously established [19]. From male 
participants, exfoliated cells from the penile glans/coronal sulcus, penile shaft, and scrotum 
were collected consecutively from each site and placed in separate collection vials as previously 
described [19]. Inner foreskin specimens were collected from uncircumcised subjects. Cervical 
cytology specimens were also obtained from female participants. Other data obtained per 
informed consent included plasma HIV RNA viral load and nadir CD4 cell count as well as age, 
gender, and ethnicity. Not all specimens and data were collected from all participants.  
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DNA from each specimen was extracted using QIAamp DNA Micro Kit (Qiagen Inc, Valencia, 
CA) and analyzed for presence or absence of HPV DNA by PCR using a modified version of the 
PGMY09/PGMY11 primer system [20]. -globin-positive and HPV DNA-positive specimens 
were genotyped using the Linear Array HPV Genotyping Test to detect 37 different HPV types 
(Roche Molecular Diagnostics, Pleasanton, CA), including 13 high-risk types (HPV 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, 68).  
Anal specimens had HIV DNA copy number quantified by real-time PCR as previously 
published [9]. Primers and probes included HIV gag (forward 5’-GAC ATC AAG CAG CCA TGC 
AA-3’; reverse 5’-CTC ATC TGG CCT GGT GCA AT-3’) and -globin (forward 5’-AGG GCC 
TCA CCA CCA ACT TC; reverse 5’-TCA CTA GCA ACC TCA AAC AGA CAC C-3’) primers; 
and VIC-labeled HIV gag (5’ACC ATC AAT GAG GAA GCT GCA GAA TGG GA-3’) and FAM-
labeled -globin (5’-CTC CTG AGG AGA AGT CTG CCG TTA CTG CC-3’) probes. Controls 
included OM10.1 cells, each carrying a single, integrated HIV provirus; and water. Assays were 
performed in triplicate. Resulting data were analyzed using StepOne Plus software (Thermo 
Fisher Scientific, Waltham, MA). Copy numbers of each target gene were calculated based on 
the standard curve, and HIV DNA copy numbers per 1 x 106 cells were determined.  
Statistical analyses were conducted by JABSOM Biostatistics & Quantitative Health Sciences. 
Mean age of participant subsets were compared using t-tests. Odds ratios (OR), 95% 
confidence intervals (CI), and p-values were calculated to investigate associations between anal 
cytology results (ASIL+ or ASIL-) and patient characteristics as well as HPV at various 
anatomical sites. For analyses, specimens were designated high-risk HPV-positive if one or 
more of 13 high-risk HPV genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) was 
detected. The numbers of HPV genotypes or high-risk HPV genotypes per specimen were 
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compared according to anal cytology results (ASIL+ or ASIL-) using Mann-Whitney tests. Kappa 
coefficient and McNemar’s test p-value were used to assess co-incident HPV genotypes. 
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RESULTS 
 
Of 61 participants (50 males, 11 females) enrolled in the study, 30 (49%) presented with ASIL. 
Data was not available to determine severity of atypical cytology. Mean age with standard 
deviation was similar for ASIL+ (50.1 ± 8.1) compared to ASIL- (47.4 ± 8.8) participants 
(p=0.275) as well as males (48.8 ± 9.1) compared to females (49.4 ± 5.2) (p=0.735) (Table 1). 
Men had significantly higher odds of presenting with ASIL: 29/50 (58%) compared to 1/11 (9%) 
women (OR=13.81, 95% CI: 1.64-116.32). Race/ethnicity was not a notable factor for ASIL: 
13/27 (48%) non-White versus 17/34 (50%) White participants (OR=0.93, 95% CI: 0.38-2.55). 
All participants were HIV-seropositive and on combination anti-retroviral therapy (cART), with 
41/48 males (85%) and 9/9 females (100%) exhibiting undetectable plasma HIV levels. Data 
regarding length of HIV infection and cART use was not collected for this study. Participants 
with detectable viral levels had higher odds of presenting with ASIL though not statistically 
significant (OR=2.93, 95% CI: 0.52-16.58) (Table 1). Likewise, nadir CD4 ≤200 cells/mm3 
conferred higher odds of ASIL but not statistically significant (OR=2.30, 95% CI: 0.80-6.61). 
Detectable HIV DNA in anal specimens was not associated with ASIL (OR=0.91, 95% CI: 0.31-
2.64). 
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Table 1. Demographic and Clinical Characteristics of Participants and Association with ASIL 
 
Anal Cytology, n   
 
Variable ASIL+ ASIL- OR 95% CI p-value 
Age (yrs.), Mean ± SD 50.1 ± 8.1 47.7 ± 8.8   0.275 
Gender (n=61) 
  
  
 
Male 29 21 13.81 1.64-116.32 0.016 
Female 1 10    
Race/Ethnicity (n=61)      
White 17 17    
Asian 4 5    
Native Hawaiian  3 5    
Native American 3 2    
African-American 2 2    
Hispanic 1 0    
Nadir CD4 (n=58)* 
  
  
 
≤200 cells/mm3 19 12 2.30 0.80-6.61 0.121 
>200 cells/mm3 11 16   
 
Plasma HIV Viral Load (n=58)* 
  
  
 
Detectable 5 2 2.93 0.52-16.58 0.223 
Not detectable 23 27   
 
Anal HIV DNA (n=59)*      
Detectable 10 11 0.91 0.31-2.64 0.861 
Not detectable 19 19   
 
ASIL = anal squamous intraepithelial lesion 
OR = odds ratio 
95% CI = 95% confidence interval 
SD = standard deviation 
* Data not available for all participants 
 
Among 52 anal specimens collected and assayed, 29 (56%) were positive for any HPV; 20 
(38%) were positive for one or more high-risk HPV genotypes (Figure 1). Genotypes detected 
most frequently in anal specimens included HPV 6 (17%) and 11 (15%), which are associated 
with genital warts; HPV 16 (19%), 52 (10%), and 68 (13%), which are high-risk types associated 
with cancer; as well as low-risk types like HPV 53 (12%), 55 (10%), 62 (17%), 66 (12%), 81 
(13%), and 84 (12%). Other HPV genotypes were detected at frequencies below 10%. 
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Figure 1. Percent frequency of HPV in anal specimens (n=52, male and female) containing any 
detectable HPV (any), one or more high-risk HPV genotypes (hr), only low-risk HPV genotypes 
(lr), or specific HPV genotypes, including 13 high-risk types associated with cancer as well as 
low-risk types 6 and 11, associated with genital warts, and others appearing at high frequency. 
 
HPV in anal specimens conferred at least two-fold higher odds of ASIL (Table 2). Detection of 
HPV 6 or 11 in anal specimens was significantly associated with ASIL (OR=6.29, 95% CI: 1.49-
26.44) while detection of any HPV approached statistical significance (OR=2.65, 95% CI: 0.86-
8.24). The number of HPV genotypes detected in anal specimens was also significantly different 
for ASIL+ (3.4 ± 3.1) versus ASIL- (1.6 ± 3.1) participants (p=0.009). 
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Table 2. Association between HPV in Anal Specimens (n=52) and ASIL 
 
Anal Cytology, n   
 
Variable ASIL+ ASIL- OR 95% CI p-value 
Any HPV 
  
  
 
Detectable 17 12 2.65 0.86-8.24 0.091 
Not detectable 8 15   
 
Any high-risk HPV 
  
  
 
Detectable 12 8 2.19 0.70-6.85 0.177 
Not detectable 13 19   
 
HPV 6 or 11      
Detectable 11 3 6.29 1.49-26.44 0.012 
Not detectable 14 24    
HPV 16 or 18      
Detectable 7 4 2.24 0.57-8.84 0.251 
Not detectable 18 23   
 
# HPV Genotypes, Mean ± SD 3.4 ± 3.1 1.6 ± 3.1   0.009 
# High-risk HPV Genotypes, Mean ± SD 1.2 ± 1.5 0.5 ± 1.2   0.105 
ASIL = anal squamous intraepithelial lesion 
OR = odds ratio 
95% CI = 95% confidence interval 
SD = standard deviation 
 
Multiple anatomical site specimens were collected from 44 males: 25 (57%) were ASIL+ while 
19 (43%) were ASIL-. HPV was detected in these specimens as follows: 27/44 (61%) anal, 
19/43 (44%) oral wash, 17/44 (39%) penile shaft, 11/43 (26%) scrotum, 10/44 (23%) penile 
head, and 0/7 foreskin. Overall, 33/44 (75%) males had at least one HPV+ specimen. HPV was 
detectable at more anatomical sites among ASIL+ (1.3 ± 1.8) versus ASIL- (0.6 ± 1.1) males 
(p=0.045). 
While 33/44 (75%) males were positive for any HPV across all anatomical sites, 25 (57%) were 
positive for one or more high-risk HPV genotypes (Figure 2). Across all specimens, genotypes 
detected most frequently among male participants included HPV 6 (30%) and 11 (18%), which 
are associated with genital warts; HPV 16 (25%), 18 (11%), 39 (16%), 45 (14%), 51 (11%), 52 
(16%), 56 (16%), and 68 (20%), which are high-risk types associated with cancer; as well as 
low-risk types like HPV 53 (11%), 55 (18%), 61 (14%), 62 (30%), 66 (20%), 72 (14%), 81 (18%),  
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Figure 2. Percent frequency of HPV in male specimens containing any detectable HPV (any), 
one or more high-risk HPV genotypes (hr), only low-risk HPV genotypes (lr), or specific HPV 
genotypes, including 13 high-risk types associated with cancer as well as low-risk types 6 and 
11, associated with genital warts, and others appearing at high frequency: A - all sites (n=44), B 
- anus (n=44), C - penile head (n=44), D - penile shaft (n=44), E - scrotum (n=43), F - oral wash 
(n=43). 
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Figure 2. (continued) Percent frequency of HPV in male specimens containing any detectable 
HPV (any), one or more high-risk HPV genotypes (hr), only low-risk HPV genotypes (lr), or 
specific HPV genotypes, including 13 high-risk types associated with cancer as well as low-risk 
types 6 and 11, associated with genital warts, and others appearing at high frequency: A - all 
sites (n=44), B - anus (n=44), C - penile head (n=44), D - penile shaft (n=44), E - scrotum 
(n=43), F - oral wash (n=43). 
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Figure 2. (continued) Percent frequency of HPV in male specimens containing any detectable 
HPV (any), one or more high-risk HPV genotypes (hr), only low-risk HPV genotypes (lr), or 
specific HPV genotypes, including 13 high-risk types associated with cancer as well as low-risk 
types 6 and 11, associated with genital warts, and others appearing at high frequency: A - all 
sites (n=44), B - anus (n=44), C - penile head (n=44), D - penile shaft (n=44), E - scrotum 
(n=43), F - oral wash (n=43). 
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83 (11%) and 84 (25%). Other HPV genotypes were detected at frequencies below 10%. In 
relation to ASIL, the number of unique HPV genotypes detected across all anatomical sites per 
participant approached statistical significance: ASIL+ (5.3 ± 5.4) compared to ASIL- (2.6 ± 4.2) 
males (p=0.054). 
For all but one association between male specimen site and HPV variable tested, detectable 
HPV corresponded with increased odds of ASIL (Table 3). In particular, detection of HPV 16 or 
18 proffered at least two-fold higher odds of ASIL across specimen types. Interestingly, penile 
shaft specimens displayed OR>3 across HPV variables. Any HPV in penile shaft specimens 
was significantly associated with ASIL (OR=6.79, 95% CI: 1.57-29.36) while detection of HPV 6 
or 11 in anal specimens approached statistical significance (OR=4.19, 95% CI: 0.97-18.12). The 
number of HPV genotypes detected at some male specimen sites also differed according to 
ASIL status: significant for anal (p=0.0496) and penile shaft (p=0.025) specimens and 
approaching significance for scrotum (p=0.087) specimens (Table 4). 
 
Table 3. Association between HPV at Male Specimen Sites and ASIL 
 
Specimen Site, OR (95% CI) 
Variable 
 
Anus 
(n=44) 
Penile 
Head 
(n=44) 
Penile 
Shaft 
(n=44) 
 
Scrotum 
(n=43) 
Oral 
Wash 
(n=43) 
Any HPV 
1.91 
(0.56-6.55) 
4.00 
(0.74-21.66) 
6.79* 
(1.57-29.36) 
2.67 
(0.60-11.92) 
1.71 
(0.50-5.86) 
Any high-risk HPV 
1.58 
(0.47-5.35) 
3.43 
(0.35-33.52) 
3.31 
(0.60-18.20) 
2.57 
(0.25-26.94) 
1.78 
(0.38-8.30) 
HPV 6 or 11 
4.19° 
(0.97-18.12) 
0.75 
(0.04-12.82) 
5.68 
(0.62-51.97) 
1.64 
(0.14-19.54) 
1.64 
(0.14-19.54) 
HPV 16 or 18 
2.07 
(0.46-9.40) 
4.15 
(0.19-91.66) 
3.43 
(0.35-33.52) 
6.35 
(0.31-130.87) 
4.33 
(0.20-96.84) 
ASIL = anal squamous intraepithelial lesion 
OR = odds ratio 
95% CI = 95% confidence interval 
* Statistically significant (p=0.010) 
° Approaching statistical significance (p=0.055) 
50 
 
Table 4. Association between Number of HPV Genotypes at Male Specimen Sites and ASIL 
 
# HPV Genotypes, 
Mean ± SD 
Specimen Site ASIL+ ASIL- p-value 
Anus (n=44) 3.4 ± 3.1 1.9 ± 3.6 0.0496 
Penile Head (n=44) 1.2 ± 2.9 0.5 ± 1.8 0.367 
Penile Shaft (n=44) 2.4 ± 4.0 0.6 ± 1.7 0.025 
Scrotum (n=43) 1.7 ± 3.6 0.5 ± 2.1 0.087 
Oral Wash (n=43) 0.8 ± 1.3 0.5 ± 0.8 0.635 
ASIL = anal squamous intraepithelial lesion 
SD = standard deviation 
 
Of 11 females enrolled in the study, only one presented with ASIL, and only one presented with 
cervical dysplasia. Odds ratios, 95% confidence intervals, and p-values were not estimable due 
to small numbers. 
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DISCUSSION 
 
Among our participants, men presented with ASIL at a higher frequency than women. Male 
participants were predominantly men who have sex with men (MSM), whose behavioral factors 
place them at higher risk for anal dysplasia/cancer [21] though such risk factors were not 
assessed in this study. Consistent with literature, female participants presented with lower rates 
of anal and cervical dysplasia. ASIL did not differ by race/ethnicity in our diverse group of 
participants. 
Previous studies have linked low CD4 cell counts to risk for ASIL. Bertisch et al. identified 
significant associations between anal cancer and low CD4 counts at nadir, at anal cancer 
diagnosis, and particularly 6-7 years before diagnosis [22]. While nadir CD4 and plasma HIV 
viral levels increased the odds of ASIL among our participants, the results were not statistically 
significant, perhaps owing to the small sample size. In the current cART era with effective 
reduction of HIV RNA to undetectable levels, presence of both HPV and residual HIV effects 
could establish a local, chronic inflammatory and metaplastic environment conducive to 
dysplastic expansion [9, 23]. Contrary to expectations, detectable HIV DNA in anal specimens 
was not associated with ASIL. 
Analysis of HPV in anal specimens did produce some results consistent with current literature 
and knowledge. HIV-seropositive patients in our study exhibited a high frequency of HPV DNA 
present in anal specimens, with HPV 16 as the most frequently occurring genotype. Like 
previous studies, detectable anal HPV and the number of anal HPV genotypes was associated 
with ASIL [5]. Our results also showed a high degree of association between HPV 6 or 11 in 
anal specimens and ASIL. Further analysis demonstrated only slight agreement between anal 
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specimens that were positive for HPV 6 or 11 and those positive for high-risk HPV (kappa=0.20, 
McNemar’s test p-value=0.11). Therefore, association between HPV 6 or 11 and ASIL is 
unlikely to be due to co-incidence of HPV 6 or 11 with high-risk HPV genotypes. Although HPV 
6 and 11 are known for causing genital warts but not cancer, the pathologist’s finding of 
abnormal cellular changes may correspond to condyloma triggered by these genotypes. 
More surprising, however, were the associations between HPV in non-anal male specimens and 
ASIL. All but one association tested displayed higher odds of ASIL among males with HPV at 
non-anal sites. The association was particularly significant for detectable HPV in penile shaft 
specimens and less so for oral wash specimens; the variability among sites was corroborated 
by analysis of association between number of HPV genotypes at specimen site and ASIL. 
Although less well-studied, especially among HIV-positive MSM, penile HPV infection and 
penile intraepithelial neoplasia (PIN) have been recorded at lower rates than anal HPV infection 
and anal intraepithelial neoplasia (AIN) [24]. In a study of 263 HIV-positive MSM in Germany, 
Kreuter et al. reported 156 (59%) cases of AIN but only 11 (4%) of PIN [25]. Moreover, only 
63% of penile cancers are attributable to HPV infection compared to 91% of anal cancers [26]. 
In light of this evidence, the high-degree of association between penile shaft HPV and ASIL in 
our study is unlikely to be due to co-incident penile dysplasia. Our discovery linking HPV at non-
anal sites to ASIL may reflect autoinoculation -- transfer of HPV from the anus to other sites by 
the participant himself -- or behavioral factors among the predominantly MSM participants 
resulting in HPV introduction across multiple anatomical sites. Nevertheless, these results 
suggest that HPV at non-anal sites may also serve as indicators for ASIL among HIV-positive 
males. 
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Previous studies of women have described strong concordance of HPV and dysplasia between 
cervical and anal sites as well as probable autoinoculation between the two [27-29]. Only one 
HIV-positive female in our study presented with ASIL, and another presented with cervical 
dysplasia. Associations between cervical HPV and dysplasia with anal HPV and dysplasia could 
not be estimated due to small sample size. 
Few studies have reported on the clinical significance of HPV in non-anal sites with respect to 
ASIL risk in HIV-seropositive individuals. Rather, studies have reported on the natural history or 
presence of HPV in multiple genital sites irrespective of ASIL [6, 7]. Our cross-sectional study 
reports for the first time that presence of HPV at multiple sites is associated with ASIL among 
HIV-positive males. Because HIV-seropositive individuals have an increased risk for anal 
dysplasia/cancer [1, 3, 30], studies that demonstrate HPV presence at non-anal sites may have 
important implications for diagnosis of anal dysplasia and for better understanding risk factors 
leading to anal cancer in the setting of HIV. 
Our study was limited by the number of participants enrolled after referral for routine anal 
dysplasia screening and by cross-sectional design. Future investigations warrant enrollment of 
larger numbers of patients to assess the relationship between ASIL and HPV at non-anal sites 
among men and women in the context of HIV. 
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 SUMMARY OF SPECIFIC AIM 1 AND NEXT DIRECTION 
 
This study aimed to determine the association between detectable HPV at various anatomical 
sites and atypical anal cytology among HIV-positive individuals in Hawaii. It did find that 
presence of HPV and the number of HPV genotypes at anatomical sites other than the anus 
trended toward higher odds of ASIL. Most interestingly, presence of HPV and the number of 
HPV genotypes at the penile shaft conferred the highest, statistically significant odds of ASIL. 
These findings suggested that markers other than HPV at the anal site may be valid predictors 
of anal dysplasia. In search of other potential diagnostic markers, the next aim considered the 
utility of HPV-16 quantitation in differentiating high-grade from low-grade anal intraepithelial 
neoplasia. 
 SPECIFIC AIM 2 
 
Differentiate high-grade anal intraepithelial neoplasia (HGAIN) from low-grade 
anal intraepithelial neoplasia (LGAIN) or negative anal biopsies using HPV type-
specific DNA quantitation. 
 
Hypothesis: HGAIN is associated with higher copy numbers of HPV-16 E6 DNA than LGAIN or 
negative anal biopsies. 
 
Rationale: While presence of HPV at multiple anatomic sites appears to be associated with 
ASIL, assessment of abnormal cytology is itself dependent on the expertise and experience of 
the pathologist. Quantitation of HPV copy numbers may provide an objective measure to 
enhance current screening algorithms for diagnosis of anal dysplasia/cancer. 
 
 
  
 
 
  
 
 
CHAPTER 3 
 
HPV-16 DNA COPY NUMBERS DIFFERENTIATE HIGH-GRADE 
FROM LOW-GRADE ANAL INTRAEPITHELIAL NEOPLASIA
63 
 
ABSTRACT 
 
Objective. Since treatment of low-grade HPV-associated anal dysplasia is currently not 
recommended, high-resolution anoscopy and biopsy of these patients may be considered 
unnecessary invasive procedures. The study’s objective was to use HPV type-specific DNA 
quantitation of anal cytology specimens to differentiate participants with high-grade anal 
intraepithelial neoplasia (HGAIN) from those with low-grade anal intraepithelial neoplasia 
(LGAIN) or negative anal biopsies in order to identify potentially avoidable HRAs with biopsy. 
Methods. Four anal cytology specimens were collected during a single visit from patients who 
consented to study while undergoing routine anal cytology screening. HRA and biopsy was 
recommended for participants with atypical anal cytology results. 
DNA extracted from anal cytology specimens was assayed for HPV-16 E6 DNA by genotype-
specific quantitative real-time polymerase chain reaction (qRT-PCR). 
Odds ratios (OR), 95% confidence intervals (95% CI), and p-values were calculated to 
investigate associations between anal cytology results and qualitative detection of HPV-16. 
HPV-16 copy numbers were analyzed by Mann-Whitney U test or Kruskal-Wallis non-parametric 
analysis of variance as appropriate. 
Results. Of 75 participants enrolled, 59% presented with anal squamous intraepithelial lesions 
(ASIL) in cytology specimens. Gender, age, race/ethnicity, smoking status, and nadir CD4 count 
did not differ between ASIL+ and ASIL- groups. 
Overall, 39% of participants had detectable HPV-16 DNA in anal cytology, which conferred 
higher odds of ASIL (OR=8.9, 95% CI: 2.7-29.7). HPV-16 DNA copy numbers per cell (mean ± 
64 
 
standard deviation) were significantly higher for ASIL+ (1115 ± 5110) versus ASIL- (45 ± 217) 
(p<0.0001). 
When cytology results were further stratified, HPV-16 DNA copy numbers per cell still varied 
significantly among HSIL (4406 ± 11010), LSIL (484 ± 1397), ASC-H (89 ± 126), ASCUS (108 ± 
312), and Negative (45 ± 217) grades (p=0.0010). When HRA biopsy results were stratified, 
HPV-16 DNA copy numbers per cell also differed significantly among HGAIN (7409 ± 14648), 
LGAIN (98 ± 192), and Negative (78 ± 136) grades (p=0.021) 
Conclusion. In conjunction with standard anal cytology screening, HPV type-specific DNA 
quantitation may allow differentiation of high-grade from low-grade anal dysplasia in order to 
reduce the number of patients for whom treatment would not be recommended after undergoing 
invasive HRA with biopsy. 
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INTRODUCTION 
 
Because HIV patients are at higher risk for anal HPV infection and associated dysplasia, it is 
recommended that they undergo annual anal cytology screening [1]. Similar to cervical cytology 
screening, anal cytologies are evaluated by a pathologist for abnormal anal squamous cells [2]. 
Atypical cytologies can be further graded as atypical squamous cells of undetermined 
significance (ASCUS), atypical squamous cells but cannot exclude high-grade (ASC-H), low-
grade squamous intraepithelial lesions (LSIL), and high-grade squamous intraepithelial lesions 
(HSIL) [3]. Micrographs in Figure 1 [4] present examples of increasingly dysplastic grades of 
mucosal epithelia in cervical tissue. 
 
 
 
Figure 1. Histological changes from Healthy to Cancer [4] 
 
When anal cytology results are atypical, patients are recommended to follow up with more 
invasive high-resolution anoscopy (HRA) and biopsy of abnormal-looking epithelia. These HRA 
biopsies are also assessed by a pathologist for diagnoses of low-grade anal intraepithelial 
neoplasia (LGAIN) or high-grade anal intraepithelial neoplasia (HGAIN). As shown in Figure 2 
[5], treatment is recommended for patients with HGAIN; however patients with LGAIN are 
usually recommended to continue annual anal cancer screening. 
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Figure 2. Anal Cancer Screening Algorithm [5] 
 
Since treatment is not recommended, the HRA and biopsy of patients with LGAIN might be 
considered unnecessary in retrospect. For this reason, RMATRIX Pilot Project RM004 was 
initiated to distinguish low-grade from high-grade disease by detection of a triad of biomarkers 
related to HIV/HPV-associated anal dysplasia: HIV DNA copy number, high-risk HPV genotypes 
HPV-16 and HPV-18, and p16 protein. As a subcomponent of RM004, HPV-16 copy numbers 
were quantified to separately evaluate the utility of HPV-16 DNA viral load in distinguishing low-
grade from high-grade disease. 
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MATERIALS AND METHODS 
 
Specimen Collection. Study protocol (CHS #21953) was approved by the UH IRB. HIV-
seropositive men and women were recruited at the Hawaii Center for AIDS Clint Spencer Clinic 
for RMATRIX Pilot Project RM004. Patients undergoing routine anal cytology screening were 
informed about the study’s purpose. If they provided written consent, four anal cytology 
specimens were collected during a single visit: one specimen was evaluated by the pathologist, 
and the rest were processed for biomarker detection. Follow-up with HRA and biopsy was 
recommended for participants receiving atypical anal cytology results per standard of care. 
Additional information was collected from participants – including gender, age, race/ethnicity, 
smoking status, and nadir CD4 count – per informed consent. 
Methodology. DNA was extracted from specimens, using the Machery-Nagel NucleoSpin Tissue 
XS Kit, and quantitated on a NanoDrop 2000 instrument. HPV-16 E6 DNA was quantified by 
genotype-specific quantitative real-time polymerase chain reaction (qRT-PCR) and normalized 
as follows: 
Based on literature research and preliminary experiments, genotype-specific primers targeting 
the HPV-16 E6 gene were selected [6]. A HPV-16 E6 gene-specific probe was designed by 
analysis of the E6 region in a published HPV-16 whole genome sequence [7], using online 
software Primer3 [8]. Primers and probe targeting -globin have previously been published [9]. 
Primer and probe sequences are listed in Table 1. Standard curves were derived from ten-fold 
serial dilutions of -globin plasmid and HPV-16 plasmid – p1203 PML2d HPV-16 was a gift from 
Peter Howley (AddGene #10869) (unpublished data) – at calculated quantities from 10 copies to 
1 million copies. Controls included DNA from SiHa cells (American Type Culture Collection 
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ATCC® HTB-35TM), positive for HPV-16; and water. All qRT-PCR assays were performed in 
triplicate, using TaqManTM Gene Expression Master Mix (Thermo Fisher Scientific, Waltham, 
MA). Representative amplification plots of HPV-16 plasmid (standard), SiHa cell DNA (positive 
control), and water (negative control) are show in Figure 3. Resulting data were analyzed using 
StepOneTM version 2.0 software (Thermo Fisher Scientific, Waltham, MA). Copy numbers of 
each target gene were calculated based on the standard curve, and HPV-16 copy numbers per 
cell were determined. 
 
Table 1. Primer/Probe Sequences for qRT-PCR 
Target Gene Primer/Probe Sequence (5’ 3’) 
HPV-16 E6 
Forward Primer 
Reverse Primer 
Probe 
  TCAAAAGCCACTGTGTCCTGA 
  CGTGTTCTTGATGATCTGCAA 
  VIC-ATATAAGGGGTCGGTGGACC-TAMRA 
-globin 
Forward Primer 
Reverse Primer 
Probe 
  AGGGCCTCACCACCAACTTC 
  TCACTAGCAACCTCAAACAGACACC 
  6FAM-CTCCTGAGGAGAAGTCTGCCGTTACTGCC-TAMRA 
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Figure 3. Quantitative real-time polymerase chain reaction (qRT-PCR) targeting HPV-16 E6 
gene. Each amplification plot displays PCR cycle number on the x-axis and Rn on the y-axis: A 
- ten-fold serially diluted HPV-16 Plasmid (standard), B - DNA from SiHa cells (positive control), 
C - water (negative control). 
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Statistics. Statistical analysis was conducted in consultation with the Office of Biostatistics and 
Quantitative Health Sciences at UH JABSOM. Based on power calculation, a sample size of 75 
was deemed sufficient to determine whether biomarker detection could differentiate high-grade 
from low-grade disease. Odds ratios (OR), 95% confidence intervals (95% CI), and p-values 
were calculated to investigate associations between anal cytology results (ASIL+ or ASIL-) and 
detectable HPV-16 in anal cytology specimens. HPV-16 copy numbers were compared between 
ASIL+ and ASIL- groups by Mann-Whitney U test. Furthermore, HPV-16 copy numbers were 
compared among patients stratified by anal cytology grade and by HRA biopsy grade, using 
Kruskal-Wallis non-parametric analysis of variance. 
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RESULTS 
 
Out of 75 participants enrolled in the study, 67 (89%) were male. Mean age was 51 years with a 
standard deviation of 10.6 years. Among this racially/ethnically diverse group, 38 (51%) were 
White, 10 (13%) Asian, 11 (15%) Hawaiian/Pacific Islander, 4 (5%) African-American, 2 (5%) 
Native/Alaskan American, and 10 (13%) identified as more than one race/ethnicity. Participants’ 
smoking status was as follows: 17 (23%) current smokers, 32 (43%) past smokers, 20 (28%) 
non-smokers. Median CD4 count at nadir was 209 cells/mm3. A summary of participant 
characteristics and association with ASIL is shown in Table 2. 
 
Table 2. Participant Characteristics and Association with ASIL 
Variable 
All Patients 
(n=75) 
ASIL+ 
 (n=44) 
ASIL- 
(n=31) 
p-value 
Age, mean (SD)  51 (10.6) 50 (9.7) 51.0 (11.9) 0.73 
Gender, n (%) Male 67 (89) 39 (89) 28 (90) 0.99 
Race/ethnicity, n (%) 
    White 
    Asian 
    Hawaiian/Pacific Islander 
    African American 
    Native/Alaskan American 
    More than One 
 
38 (51) 
11 (15) 
10 (13) 
4 (5) 
2 (3) 
10 (13) 
 
22 (50) 
7 (16) 
4 (9) 
3 (7) 
1 (2) 
7 (16) 
 
16 (52) 
4 (13) 
6 (19) 
1 (3) 
1 (3) 
3 (10) 
0.79 
Smoking, n (%) 
    Current Smoker 
    Past Smoker 
    Never Smoked 
 
19 (25) 
36 (48) 
20 (27) 
 
13 (30) 
19 (43) 
12 (27) 
 
6 (19) 
17 (55) 
8 (26) 
0.53 
CD4 nadir count, median 209 193 233 0.35 
ASIL = anal squamous intraepithelial lesion 
SD = standard deviation 
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Of the 75 participants, 44 (59%) presented with anal squamous intraepithelial lesions (ASIL) in 
cytology specimens. None of the characteristics listed above – gender, age, race/ethnicity, 
smoking status, and nadir CD4 count – differed statistically between those with normal versus 
atypical anal cytology. 
Overall, 29 (39%) participants had detectable HPV-16 DNA in anal cytology specimens. Of the 
44 participants with ASIL, 25 (57%) had detectable HPV-16 DNA in anal cytology specimens. 
Those with detectable HPV-16 DNA had significantly higher odds of presenting with ASIL 
(OR=8.88, 95% CI: 2.66-29.72) (p=0.0001). HPV-16 DNA copy numbers (mean ± standard 
deviation) also differed significantly between the ASIL+ (1115 ± 5110) and ASIL- (45 ± 217) 
groups (p<0.0001). These statistics are summarized in Table 3. 
 
Table 3. Association between HPV-16 in Anal Specimens (n=75) and ASIL 
 
Anal Cytology, n   
 
Variable ASIL+ ASIL- OR 95% CI p-value 
HPV-16 
  
  
 
Detectable 25 4 8.88 2.66-29.72 0.0001 
Not detectable 19 27   
 
HPV-16 copies per cell, Mean ± SD 1115 ± 5110 45 ± 217   <0.0001 
ASIL = anal squamous intraepithelial lesion 
OR = odds ratio 
95% CI = 95% confidence interval 
SD = standard deviation 
 
When atypical cytology results were further stratified, 9 (12%) were graded HSIL, 15 (20%) LSIL, 
2 (3%) ASC-H, 18 (24%) ASCUS, and 31 (41%) Negative. As shown in Figure 4, the proportion 
of participants with detectable HPV-16 DNA varied according to anal cytology grade: 7 (78%) of 
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HSIL, 9 (60%) of LSIL, 1 (50%) of ASC-H, 8 (44%) of ASCUS, and 4 (13%) of Negative. 
However, these differences were not statistically significant. 
 
 
Figure 4. HPV16+ Proportion and Percent of Cytology Specimens by Anal Cytology Grade. 
Detectable HPV-16 DNA varied according to anal cytology grade, but differences were not 
statistically significant. 
 
As pictured in Figure 5, HPV-16 DNA copy numbers per cell (mean ± standard deviation) also 
varied according to anal cytology grade: HSIL (4406 ± 11010), LSIL (484 ± 1397), ASC-H (89 ± 
126), ASCUS (108 ± 312), and Negative (45 ± 217) grades differed significantly (p=0.0010) by 
Kruskal-Wallis non-parametric analysis of variance. 
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Figure 5. HPV16 Copy Number by Anal Cytology Grade. HPV-16 copies per cell differed 
significantly among anal cytology grades (p=0.0010). Bar represents median value in group. 
 
Follow-up HRA and biopsy was recommended for participants with atypical anal cytology results. 
For the 16 participants who did undergo HRA, biopsy grades were as follows: 5 (31%) HGAIN, 8 
(50%) LGAIN, and 3 (19%) Negative. As depicted in Figure 6, the proportion of participants with 
detectable HPV-16 DNA varied according to anal cytology grade: 5 (100%) of HGAIN, 6 (75%) 
of LGAIN, and 1 (33%) of Negative. However, these differences were not statistically significant. 
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Figure 6. HPV16+ Proportion and Percent of HRA Biopsy Specimens by Grade. Qualitative 
differences in HPV-16 detection among HRA biopsy grades were not statistically significant. 
 
As illustrated in Figure 7, HPV-16 DNA copy numbers per cell (mean ± standard deviation) also 
varied according to HRA biopsy grade: HGAIN (7409 ± 14648), LGAIN (98 ± 192), and Negative 
(78 ± 136) grades differed significantly (p=0.021) by Kruskal-Wallis non-parametric analysis of 
variance. A threshold line drawn at 10 copies per cell neatly demarcates all participants with 
HGAIN while three others with LGAIN and another with Negative biopsy results also had HPV-
16 E6 copy numbers above 10 copies per cell. 
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Figure 7. HPV16 Copy Number by HRA Biopsy Grade. HPV-16 copies per cell differed 
significantly among HRA biopsy grades (p=0.021). Bar represents median value in group. 
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DISCUSSION 
 
Consistent with a previous study of anal dysplasia among HIV+ patients in Hawaii [9], 
participants in this study were predominantly male and racially/ethnically diverse, and there was 
no significant difference in age or race/ethnicity between participants with ASIL and those 
without. Unlike the previous study, females in this study presented with ASIL at approximately 
the same frequency as males. This discrepancy may be attributable to the low number of 
females enrolled in both studies. 
 Other researchers have noted an association between cigarette smoking and HPV infection or 
HPV-associated dysplasia. In a study of HIV+ MSM, Wieland et al. found higher frequency of 
anal dysplasia and higher HPV-16 viral loads among smokers compared to non-smokers [10]. 
This study revealed no difference in ASIL occurrence among HIV+ participants who were 
current smokers, past smokers, or never smokers. Further analysis is necessary to investigate 
whether HPV-16 viral loads differ among these groups. Other researchers have also linked 
nadir CD4 cell counts of HIV+ patients to risk for ASIL [11]. No association between ASIL and 
nadir CD4 counts appeared in this study. 
Overall, the proportion of participants who presented with ASIL (59%) in anal cytology 
specimens was also similar to the previous study of anal dysplasia among HIV+ patients in 
Hawaii [9]. As expected, ASIL+ participants were also more likely to have detectable HPV-16 E6 
DNA as well as greater HPV-16 E6 copies per cell than ASIL- participants. When integrated into 
infected host cells, the HPV E6 oncogene can be transcribed and translated into oncoprotein 
that disrupts p53-regulated cell cycle checkpoints to induce unregulated cellular proliferation 
indicative of cancer [12]. Presence of HPV-16 E6 DNA, particularly at higher copy numbers, 
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suggests replication of viral oncogenes with potential to transform infected host cells. Such 
cellular transformation may be recognized as dysplasia by pathologists assessing cytology and 
biopsy specimens. 
Upon further stratification of anal cytology results, participants with HSIL were most likely to 
have detectable HPV-16 E6 DNA, trailed by those with LSIL, then ASC-H, ASC-US, and 
Negative cytology results. Although higher grades of anal dysplasia corresponded to greater 
frequency of HPV-16 detection, differences among grades were not statistically significant. 
HPV-16 E6 copy numbers followed a similar trend with highest mean copies per cell in 
participants with HSIL then LSIL, ASC-US, ASC-H, and Negative cytology results. These 
differences in copy number were statistically significant. 
Likewise, stratification of HRA biopsy results revealed greater frequency of HPV-16 detection in 
specimens with higher grades anal dysplasia: 100% of those with HGAIN tested positive for 
HPV-16 E6 DNA in anal cytology. Here again, mean HPV-16 E6 copies per cell were 
significantly higher in those with HGAIN relative to LGAIN and Negative biopsy results.  
Although only the five participants with HGAIN (31%) out of sixteen who underwent HRA with 
biopsy would have been referred for treatment, three others with LGAIN and another with 
Negative biopsy results had HPV-16 E6 copy numbers within range of those with HGAIN as 
illustrated in Figure 7. While the screening algorithm recommends annual HRA follow-up for 
those with LGAIN, it may be reasonable to recommend the same for the individual with Negative 
biopsy results but high HPV-16 copy numbers. Furthermore, it is worth considering whether 
invasive HRA with biopsy was necessary for the remaining seven (44%) with LGAIN or Negative 
biopsy results and low HPV-16 E6 copy numbers. 
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Assessment of cytology and biopsy specimens is known to be somewhat subjective, dependent 
on the experience and expertise of the pathologist. As part of the ASCUS-LSIL Triage Study, 
Stoler et al. found only moderate agreement among even well-trained pathologists examining 
cervical cytology (kappa = 0.46, 95% CI: 0.44-0.48) and biopsy (kappa = 0.46; 95% CI, 0.43-
0.49) specimens [13]. Baena et al. recently published an article describing similar inter-observer 
reproducibility (median kappa = 0.51) for cervical cytology evaluation, with overall false-positive 
rate of 31% and false-negative rate of 11% [14]. Incorporating HPV quantitation in anal 
dysplasia screening may improve diagnostic accuracy with the benefit of reducing patient 
discomfort from potentially unnecessary invasive procedures and anxiety induced by false-
positive results. 
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 SUMMARY OF SPECIFIC AIM 2 AND NEXT DIRECTION 
 
This study aimed to differentiate high-grade anal intraepithelial neoplasia (HGAIN) from low-
grade anal intraepithelial neoplasia (LGAIN) or negative anal biopsies using HPV type-specific 
DNA quantitation. Based on the HPV-16 qRT-PCR data and available biopsy reports, all 
participants with HGAIN also had detectable HPV-16 E6 DNA above a threshold of 10 copies 
per cell. However, some participants with LGAIN or Negative biopsies also had detectable HPV-
16 E6 DNA above a threshold of 10 copies per cell. Since cytology and biopsy results are 
dependent on the pathologist’s expertise and experience, HPV quantitation may prove useful as 
an objective supplemental diagnostic marker. 
Thus far the relationship between HPV and anal dysplasia has been examined in the context of 
prior HIV infection. The next aim probed the converse relationship on this axis – the acquisition 
of HIV after HPV infection. 
 SPECIFIC AIM 3 
 
Determine whether an association exists between HIV seroconversion and 
acquisition or clearance of anal HPV genotypes in a Thai cohort. 
 
Hypothesis: HPV clearance is associated with HIV seroconversion in a high-risk population. 
 
Rationale: As previously demonstrated, HIV-positive individuals frequently present with HPV at 
multiple anatomical sites in association with anal dysplasia/cancer, and HPV quantitation may 
enhance current screening methods for diagnosis of HPV-associated anal dysplasia/cancer in 
the context of HIV infection. Better understanding of HPV’s role in subsequent HIV 
seroconversion could suggest a novel strategy for reducing HIV transmission. 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
 
ANAL HPV ACQUISITION INCREASED HIV SEROCONVERSION RISK 
IN THAILAND TEST & TREAT COHORT 
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ABSTRACT 
 
Objective. Previous studies suggest an association between HPV acquisition or clearance and 
HIV seroconversion. This study sought to determine whether anal HPV acquisition or clearance 
was associated with HIV seroconversion among the Thai Test & Treat cohort. 
Methods. From Thai MSM and TG women, ages 18 and older, with no previous HIV-positive 
test, who were enrolled in the parent Test & Treat study, 24 HIV serconverter cases were 
selected and matched to 48 HIV-negative controls. Cases and controls had anal cytology 
specimens collected twice within a twelve-month period. DNA previously extracted from anal 
cytology specimens were assayed, using Roche’s LINEAR ARRAY HPV Genotyping Test 
Conditional logistic regression models were applied; and odds ratios, 95% confidence intervals, 
and p-values were calculated to determine whether an association existed between anal HPV 
acquistion or clearance and HIV seroconversion. 
Results. Acquisition of any HPV genotype (OR=4.75, 95% CI: 1.01-22.32, p=0.049) or any 
high-risk HPV genotype (OR=4.93, 95% CI: 1.36-17.96, p=0.015) conferred higher odds of HIV 
seroconversion. Clearance of any HPV genotype (OR=1.64, 95% CI: 0.56-4.85, p=0.37) or any 
high-risk HPV genotype (OR=1.16, 95% CI: 0.46-2.91, p=0.75) was not significantly associated 
with HIV seroconversion. 
Conclusion. HPV acquisition not clearance was associated with HIV seroconversion in the Thai 
Test & Treat cohort. Clarification of HPV’s role in HIV acquisition may suggest a new approach 
for reducing HIV transmission. 
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INTRODUCTION 
 
Thailand is one of five Southeast Asian countries that together account for 99% of the region’s 
HIV burden [1]. Despite declining incidence, Thailand witnessed an estimated 8800 new HIV 
infections in 2012; adult HIV prevalence remains about 1% [2].  Populations at higher risk of 
acquiring HIV infection include men who have sex with men (MSM) and transgender (TG) 
people.  HIV prevalence among MSM is 7.1% in Thailand and 24.7% in Bangkok [3].  HIV 
prevalence among TG people is 10.4% in Thailand and 7.7% in Bangkok [4]. 
In order to further suppress transmission of HIV, the Thai Red Cross AIDS Research Centre 
(TRCARC) with support from the Thai Ministry of Public Health initiated a “Test & Treat” protocol 
to encourage regular visits for voluntary counseling and testing (VCT) among MSM and TG 
women and to make available anti-retroviral therapy (ART) to those who test HIV-positive, 
regardless of CD4 count. Although participants entered the study with no previous HIV-positive 
test, some acquired HIV during the two-year follow-up period. The primary outcome measure for 
Test & Treat was ART uptake at HIV seroconversion.  
HIV-positive patients are at higher risk of acquiring HPV [5] even while on ART [6].  Infection 
with high-risk HPV genotypes in the anogenital region can lead to dysplasia, which can progress 
to cancer.  HIV and HPV can both be contracted via sexual transmission; deposition or infection 
by both viruses can occur at the same tissue sites.  While many studies have examined HPV as 
a consequence of HIV infection, few have scrutinized HPV as a precursor to HIV infection.  Two 
meta-analyses suggest an association between HPV infection and HIV acquisition [7, 8].  Two 
other studies demonstrate an association between HPV clearance and HIV seroconversion [9, 
10].  This substudy of the Test & Treat protocol sought to determine whether anal HPV 
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acquisition or clearance was associated with HIV seroconversion among Thai MSM and TG 
women. Clarification of HPV’s role in HIV acquisition may suggest a new approach for reducing 
HIV transmission. 
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MATERIALS AND METHODS 
 
Specimen Collection. The parent Test & Treat protocol was approved by the Chulalongkorn 
University IRB, and enrollment began at TRCARC’s Anonymous Clinic. Inclusion criteria were 
Thai MSM and TG women, ages 18 and older, no previous HIV-positive test. An amendment to 
the Test & Treat protocol to allow specimen access for this substudy was also approved by the 
Chulalongkorn University IRB. The proposal submitted to the UH IRB was granted exempt 
status. This substudy utilized DNA previously extracted from anal cytology specimens for the 
parent Test & Treat protocol. Participants included in the substudy had at least two anal 
cytology specimens collected within a twelve-month period. 
Methodology. HIV serconverter cases from whom anal cytology specimens were collected at 
HIV seroconversion and within twelve months prior were selected and matched to HIV-negative 
controls from whom anal cytology specimens were collected twice within a twelve-month period. 
Matching criteria included the following: age, number of partners during the previous month, and 
inconsistent condom use during the previous month. DNA previously extracted from anal 
cytology specimens were assayed, using Roche’s LINEAR ARRAY HPV Genotyping Test to 
detect up to 37 HPV genotypes, including 13 high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 68) associated with cancer. 
Statistics. A power calculation found that 24 HIV seroconverter cases matched to 48 HIV-
negative controls would be sufficient to determine whether an association between HPV 
acquistion or clearance and HIV seroconversion existed. Change in HPV genotypes detected at 
timepoint1 (T1) versus timepoint2 (T2) for each HIV seroconverter case compared to matched 
HIV-negative controls was analyzed. Conditional logistic regression models were applied; and 
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odds ratios, 95% confidence intervals, and p-values were calculated to determine whether an 
association existed between anal HPV acquistion or clearance and HIV seroconversion. 
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RESULTS 
 
Out of 498 MSM and TG women enrolled in the parent Test & Treat study in Bangkok, 112 
(22%) tested HIV-positive at baseline and were excluded from the retrospective case-control 
substudy. Of the remaining participants, 37 seroconverted, testing HIV-positive during follow-up. 
As shown in Figure 1, a total of 24 HIV serconverter cases from whom anal cytology specimens 
were collected at HIV seroconversion and within twelve months prior were selected and 
matched to 48 HIV-negative controls from whom anal cytology specimens were collected twice 
within a twelve-month period. 
 
 
 
Figure 1. Retrospective Case-Control Substudy Design 
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DNA from anal cytology specimens at both timepoint1 (T1) and timepoint2 (T2) for all 24 
selected HIV seroconverter cases produced valid HPV genotyping results. However, among 48 
matched HIV-negative controls, two produced invalid HPV genotyping results at T1. A third 
matched control was found not to have met the criterion for two anal cytology specimens 
collected within a twelve-month period; therefore DNA from that participant’s anal cytology 
specimens was not tested. All valid HPV genotyping tests were included for the purpose of 
calculating genotype frequency. Three controls were excluded from analysis of HPV association 
with HIV seroconversion due to the aforementioned invalid HPV genotyping tests and unmet 
inclusion criterion. 
Among cases, the frequency of high-risk HPV genotypes 18, 45, 51, 52, 59, and 68 in anal 
cytology specimens increased during the period between T1 to T2 while frequency of high-risk 
HPV genotypes 31, 33, 35, and 56 decreased. In particular, types 18 and 52 displayed the 
overall highest frequency (33.3%) among cases at T2. A few high-risk HPV genotypes were 
detected at consistent frequencies from T1 to T2: types 16 (25.0%), 39 (12.5%), 58 (20.8%). 
During the same timeframe, low-risk HPV genotype 6 increased while 11 decreased in 
frequency among cases. Frequency in anal cytology specimens of 37 HPV genotypes detected 
by the Roche LINEAR ARRAY HPV Genotyping Test is shown in Table 1. Frequency of 13 
high-risk HPV genotypes and select low-risk genotypes are graphed in Figure 2. 
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Table 1.  Frequency in anal cytology specimens of 37 HPV genotypes 
detected by the Roche LINEAR ARRAY HPV Genotyping Test 
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In contrast, frequency of HPV genotypes in anal cytology specimens from matched controls 
exhibited rather less dramatic change from T1 to T2. High-risk HPV genotypes 16, 33, 39, 52, 
58, and 59 increased modestly while high-risk HPV genotypes 18, 31, and 45 decreased 
modestly. High-risk types 35, 51, 56, and 68 changed negligibly as did low-risk HPV genotypes 
6 and 11. Nonetheless, HPV 16 was the most frequently detected HPV genotype in anal 
cytology specimens from matched controls at both T1 and T2. 
Overall, detection of any HPV genotype in anal cytology specimens from cases increased from 
79.2% to 91.7% while any high-risk (HR) HPV genotype increased from 66.7% to 83.3% during 
a mean interval of 34.5 weeks between T1 and T2. For matched controls, any HPV genotype 
rose moderately from 71.1% to 76.6% while any HR HPV genotype rose slightly from 62.2% to 
63.8% during a mean interval of 48.2 weeks between T1 and T2. These statistics are 
summarized in Table 2 and graphed in Figure 3. 
 
Table 2.  Frequency in anal cytology specimens of any detectable HPV genotype 
or any detectable high-risk HPV genotype during interval T1 to T2 
 
Frequency (%) 
 
Cases T1 Cases T2 Controls T1 Controls T2 
 Any HPV  79.2 91.7 71.1 76.6 
 Any HR HPV 66.7 83.3 62.2 63.8 
 Mean time from T1 to T2 34.5 weeks 48.2 weeks 
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Figure 3. Frequency in anal cytology specimens of any HPV genotype or  
any high-risk HPV genotype for cases and matched controls at T1 and T2 
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When conditional logistic regression models were applied, HPV acquisition not clearance was 
associated with HIV seroconversion. Acquisition of any HPV genotype and acquisition of any 
HR HPV genotype conferred higher odds for HIV seroconversion: OR=4.75, 95% CI: 1.01-22.32 
(p=0.049) and OR=4.93, 95% CI: 1.36-17.96 (p=0.015), respectively. In comparison, clearance 
of any HPV genotype or clearance of any HR HPV genotype was not significantly associated 
with HIV seroconversion: OR=1.64, 95% CI: 0.56-4.85 (p=0.37) and OR=1.16, 95% CI: 0.46-
2.91 (p=0.75), respectively. These statistics are summarized in Table 3.  
 
Table 3. Conditional logistic regression models for odds of HIV seroconversion 
 
OR = odds ratio 
LCI = lower 95% confidence interval 
UCI = upper 95% confidence interval 
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DISCUSSION 
 
Among cases in this study, more oncogenic HPV genotypes increased than decreased in 
frequency in anal cytology specimens by HIV seroconversion visit, with types 18 and 52 in 
particular rising dramatically by T2 to 33.3% each. Meanwhile, frequency of low-risk genotypes 
associated with genital warts also changed significantly: HPV-6 surged (4.2% to 16.7%) while 
HPV-11 declined sharply (25% to 12.5%) among cases during the same time period. In contrast, 
the shift in frequency of detectable HPV genotypes in anal cytology specimens from matched 
controls generally occurred in only modest increments. Interestingly, oncogenic HPV-16, which 
is typically the most prevalent type in HPV-associated dysplasia/cancer, maintained relatively 
stable frequencies among both HIV seroconverter cases (25%) and matched HIV-negative 
controls (20% to 21.3%). 
The overarching trends are reflected in the changing frequencies of any detectable HPV 
genotype and any high-risk (HR) HPV genotype, with more evident increases among HIV 
seroconverter cases (>12%) compared to matched HIV-negative controls (<6%). Analysis using 
conditional logistic regression models did find an association between acquisition of any HPV 
genotype or any HR HPV genotype and HIV seroconversion. Clearance of any HPV genotype 
or any HR HPV genotype was not associated with HIV seroconversion. 
Due to its retrospective case-control design, this study was limited to specimens previously 
collected for the parent Test & Treat study. T2 anal cytology specimens for cases were collected 
at HIV seroconversion visit. More frequently collected anal cytology specimens and 
corresponding HIV serology were not available to ascertain timepoint of HIV acquisition relative 
to HPV detection. While this study did find an association between HPV acquisition and HIV 
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seroconversion, it is possible that increased HPV acquisition occurred not as a precursor but as 
a consequence of acute HIV infection. In addition, analyzing the acquisition or clearance of any 
detectable HPV genotype or any HR HPV genotype as a group may dampen the apparent effect 
of acquisition or clearance of any individual HPV genotype. Unfortunately, the study was not 
designed to perform this type of analysis, and its sample size and statistical power were 
inadequate for such. 
Nonetheless, a growing body of literature now exists, including two meta-analyses [7, 8] 
supporting the interpretation that HPV infection increases the risk of subsequent HIV acquisition. 
While the majority of original research citations examine HPV infection and associated HIV 
acquisition among women [10-15], others reach similar conclusions about HPV infection and 
HIV acquisition among men. Chin-Hong et al. found an association between anal HPV infection 
and HIV acquisition among MSM, independent of sexual activity, substance use, and other 
sexually transmitted infections [16]. Meanwhile, Tobian et al. established an association 
between clearance of penile HPV infection and HIV acquisition among Ugandan men [9]. 
Although the exact nature of HPV infection’s influence on HIV acquisition is not yet understood, 
some researchers believe there is sufficient evidence to investigate the effect of HPV 
vaccination on HIV incidence. In journal commentaries, van der Loeff et al. have advocated for 
rigorous randomized control trials [17] while Rositch et al. have promoted mass vaccination and 
surveillance in countries with high HIV incidence as a more ethical and cost-effective approach 
[18]. In the absence of an effective HIV vaccine, HPV vaccination could prove a novel strategy 
for reducing the global incidence of HIV. 
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 SUMMARY OF SPECIFIC AIM 3 
 
This study aimed to determine whether an association exists between HIV seroconversion and 
acquisition or clearance of anal HPV genotypes. Based on data from the Thai Test & Treat 
cohort, HPV acquisition not clearance was associated with HIV seroconversion. While some 
researchers have published similar results, others concluded that HPV clearance was 
associated with HIV acquisition. If further research confirms HPV’s role in subsequent HIV 
acquisition, HPV vaccination could prove a novel strategy for reducing the global incidence of 
HIV. 
  
 
 
 
 
 
 
CHAPTER 5 
 
SUMMARY AND FUTURE DIRECTIONS 
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SUMMARY 
 
The central objective of this study was to further elucidate the relationship between HIV and 
HPV infection in anal dysplasia/cancer by assessing HPV infection in the context of HIV and 
vice versa. A substantial catalog of scientific literature has consistently found increased 
incidence of HPV in the wake of HIV infection. Even while on effective cART, HIV patients are 
more susceptible to HPV infection and associated dysplasia/cancer. Although less well-studied, 
a growing body of literature suggests that the reverse is also true: HPV infection increases the 
risk of subsequent HIV acquisition. This study was designed with these bi-directional 
interactions in mind.       
First, the study demonstrated that HPV at non-anal sites may be associated with anal 
dysplasia/cancer among HIV-positive males. The presence of HPV and the number of HPV 
genotypes at anatomical sites other than the anus trended toward higher odds of ASIL. 
Surprisingly, presence of HPV and the number of HPV genotypes at the penile shaft conferred 
the highest, statistically significant odds of ASIL – greater odds than conferred by presence of 
HPV and the number of HPV genotypes at the anus itself. HPV at non-anal sites may be linked 
to ASIL due to autoinoculation – transfer of HPV between sites by the participant himself – or to 
behavioral factors among the predominantly MSM participants resulting in HPV introduction 
across multiple anatomical sites. Regardless, these data suggest that HPV detection at non-
anal sites may be useful indicators of ASIL risk among HIV-positive males. 
Second, the study showed the potential of HPV quantitation for enhanced screening and 
diagnosis of anal dysplasia/cancer in the context of HIV infection. Here, all participants with 
HGAIN had HPV-16 E6 DNA levels above 10 copies per cell. Three participants with LGAIN and 
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one with a Negative biopsy also had detectable HPV-16 E6 DNA above a threshold of 10 copies 
per cell. While the anal cancer screening algorithm recommends annual HRA follow-up for 
those with LGAIN, perhaps the same recommendation should apply for those with Negative 
biopsy results but high HPV-16 copy numbers. For the remaining seven participants with LGAIN 
or Negative biopsy results, their low HPV-16 E6 copy numbers beg the question whether 
invasive HRA with biopsy could have been avoided. Since cytology and biopsy results are 
known to be dependent on the pathologist’s expertise and experience, HPV quantitation may 
prove useful as an objective supplemental diagnostic marker. 
Third, the study explored the effect of prior HPV infection on acquisition of HIV. Among MSM 
and TG women in the Thai Test & Treat cohort, HPV acquisition appeared to increase the risk of 
subsequent HIV seroconversion. While there are previous publications supporting this 
conclusion, others instead link HPV clearance to HIV acquisition. Despite remaining ambiguity 
over HPV’s role in HIV acquisition, some researchers are advocating for study of HPV 
vaccination as a means for reducing HIV incidence. 
In its entirety, this study has contributed to the body of knowledge in the field by identifying new 
diagnostic indicators of HPV-associated anal dysplasia and by providing additional evidence for 
HPV’s influence on HIV acquisition. Further investigation will permit validation of these novel 
diagnostic markers and innovative strategy for reducing the global incidence of HIV. 
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FUTURE DIRECTIONS 
 
The Hawaii HIV Laboratory (HHIVL) continues to explore the relationship between HIV and HPV 
infection. An upcoming project will investigate differences or similarities in biomarkers and risk 
factors influencing development of anal neoplasia between HIV-serodiscordant partners. An 
additional component will evaluate Raman spectroscopy of anal biopsies as a potential 
diagnostic tool in screening for anal cancer. 
The second year of RMATRIX Pilot Project RM004 is in progress with anal cytology specimens 
collected outside the clinic by participants themselves, using a mail-in kit designed by HHIVL. 
As in year one, the same triad of biomarkers (HIV DNA copy number, high-risk HPV copy 
numbers, and p16 protein) are being assessed for association with anal dysplasia. In addition to 
HPV-16 E6 DNA copy numbers, HPV-18 E7 DNA copy numbers are also being assayed. If 
comparable to data from year one when specimens were collected in the clinic, results from 
year two will validate the feasibility of self-collection mail-in kits as well as the utility of 
biomarkers including HPV-16 E6 DNA copy numbers for anal cancer screening. It is also hoped 
that a kit for self-collection of specimens will reduce stigma and other barriers to access for anal 
cancer screening. 
A currently unfunded research project proposes to exploit recent advances in flow cytometry to 
distinguish cells from anal cytology specimens that express high versus low levels of HPV type-
specific mRNA and protein. High-expression cells would be sorted separately from low-
expression cells. Extracted total nucleic acid could be assayed not only for HPV type-specific 
DNA copy number but also for differential expression of other genes not typically linked to HPV 
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infection. Network analysis could pinpoint signaling pathways that influence development of 
HPV-associated anal dysplasia and cancer. 
Meanwhile, as more evidence supporting the association between prior HPV infection and 
subsequent HIV acquisition has accumulated, some researchers have begun to advocate for 
studies examining the use of HPV vaccination to reduce HIV incidence. The debate about best 
approach – randomized control trial versus mass vaccination and surveillance – has already 
begun. In the absence of an effective HIV vaccine, HPV vaccination could prove a novel 
strategy for reducing the global incidence of HIV.  
 
 
